Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-26

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized clinical trial to determine whether a probiotic formulation containing 4 probiotic strains which belong to Lactiplantibacillus plantarum and Pediococcus acidilactici species can boost the immune response to influenza vaccination evaluated at 4 weeks in a population between 50 and 80 years of age. Secondary outcomes comprise evaluation of immune response at 8 weeks after vaccination, percentage of patients with seroconversion, incidence and duration of influenza-like infections and respiratory infections throughout a 4-month period and safety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.

NCT03167593

Influenza Vaccination Immune Response Probiotics

COMPLETED PHASE2

Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination

NCT06103994

Influenza

COMPLETED NA

Probiotic, Prebiotic and Synbiotic Effect on Immunity

NCT01084434

Dietary Intervention

UNKNOWN NA

Probiotics and Influenza Vaccination Response

NCT05690373

Vaccine Response

COMPLETED NA

Immune System Stimulation by Probiotic Food Supplementation

NCT03049579

Flu Symptom

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Double blind, randomized, placebo-controlled clinical trial to determine whether supplementation with a probiotic formulation containing 4 probiotic strains (L. plantarum CECT 30292, CECT7484, CECT7485 and P. acidilactici CECT7483) can improve immune response to seasonal influenza vaccination. Subjects with age comprised between 50 and 80 years who meet inclusion and exclusion criteria will be randomized 1:1 to one of the following study groups: one will receive probiotic formulation for 28 days (1 capsule/day) and the other will receive placebo, starting the same day of the influenza vaccination. Main study outcome will be immune response at 4 weeks after vaccination, which will be determined by analysis of specific IgG antibodies in serum against influenza A and B. Secondary outcomes comprise serum titers of specific IgG at 8 weeks after vaccination, percentage of patients with seroconversion at 4 and 8 weeks, evaluation of influenza-like infections or respiratory infections throughout a 4-month period and adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind, randomized controlled trial in 140 subjects 50-80 years old receiving influenza vaccination, who will be allocated to receive either an experimental product containing multi-strain probiotic formula or placebo for 28 days

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Both placebo and active product will be provided in identical packaging.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority

Group Type EXPERIMENTAL

Food Supplement

Intervention Type DIETARY_SUPPLEMENT

Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination

Placebo

Maltodextrin (E1400, qs) in HPMC capsules

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Food Supplement

Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination

Intervention Type DIETARY_SUPPLEMENT

Placebo

One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Probiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects 50 - 80 years old receiving seasonal Influenza vaccine in season 2021-2022
* Body mass index (BMI) 18.5-34.9 kg/m2
* Willing to provide informed consent
* Able to follow study procedures, according to the criteria of study investigator

Exclusion Criteria

* Hypersensitivity to any of the components of influenza vaccine
* Previous influenza infection in the same season (from 01/09/2021)
* Having received influenza vaccination in the previous season less than 9 months before study entry (from 01/01/2021)
* Having received another vaccine -different from COVID19 vaccine- up to 1 month before study inclusion or planning to receive it 1 month after study inclusion
* Active infection at the moment of study entry as diagnosed by study physician
* History of severe allergic reactions (food and non-food), including severe asthma.
* Receiving immunosuppressant therapy, displaying neutropenia, lymphopenia, AIDS, immunoglobulin deficiency, active oncological disease.
* Daily ingestion of any food complement or food added with probiotics (including Actimel o similar products) 2 weeks before inclusion in the study
* Acute pancreatitis, short bowel syndrome or active inflammatory bowel disease
* Diagnosed from other pathologies that according to study physician may compromise the immunological function of the individual (such as immunodeficiencies, lupus, multiple sclerosis, among others)
* Having received antibiotic treatment in the previous month

* Withdrawal from the study as per study investigator criteria, in case that study procedures are not followed by the participant
* In case of adverse event that prevents them from following study procedures or complying with the treatments under study.
* Failure to comply with study procedures: Complete less than 70% of the days in the patient's diary and/or take less than 80% of the days of the study products.
* Receive any of the unauthorized treatments indicated in the selection criteria, with the exception of antibiotics that will be allowed under medical prescription.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes